



Arthur Pinaría <arthur.pinaría@unsrat.ac.id>

**You are co-author of a submitted article**

1 message

**Journal of Advanced Biotechnology and Experimental Therapeutics**

13 September 2021 at 22:42

<noreply@ejmanager.com>

Reply-To: Journal of Advanced Biotechnology and Experimental Therapeutics <jabet.editor@gmail.com>

To: arthur.pinaría@unsrat.ac.id

Dear Arthur Pinaría,

You are co-author in an article submitted to **Journal of Advanced Biotechnology and Experimental Therapeutics** and entitled **Morphology, Diversity and Phylogenetic Analysis of Spodoptera exigua (Lepidoptera: Noctuidae) in North Sulawesi by Employing Partial Mitochondrial Cytochrome Oxidase I Gene Sequences** (Manuscript Number: JABET-2021-09-084).

Corresponding author: Talha Bin Emran (talhabmb@bgctub.ac.bd)

If you think that you should not be one of the authors in this manuscript, please contact the editorial office (jabet.editor@gmail.com). If you are a co-author for this paper, no further action is needed.

Thank you for submitting your work to our journal.

Best regards,

Editor  
Journal of Advanced Biotechnology and Experimental Therapeutics  
<http://www.bsmiab.org/jabet>

\*\*\*\*\*

JOURNAL CONTACT EMAIL: [jabet.editor@gmail.com](mailto:jabet.editor@gmail.com)

IMPORTANT: USE JOURNAL CONTACT EMAIL for your messages. Do not answer to this email. It is not checked for messages

<http://www.ejmanager.com>

\*\*\*\*\*

**UNSRAT**

Arthur Pinaría &lt;arthur.pinaría@unsrat.ac.id&gt;

**Fwd: Article Revision Letter for Authors - (JABET-2021-09-084)**

1 message

Trina Tallei <talleitrina@gmail.com>  
 To: arthur.pinaría@unsrat.ac.id

30 September 2021 at 12:26

----- Forwarded message -----

From: **Dr. Talha Bin Emran** <talhabmb@bgctub.ac.bd>  
 Date: Thu, Sep 30, 2021 at 12:10 PM  
 Subject: Fwd: Article Revision Letter for Authors - (JABET-2021-09-084)  
 To: Trina Tallei <trina\_tallei@unsrat.ac.id>, Trina Tallei <talleitrina@gmail.com>

----- Forwarded message -----

From: **Journal of Advanced Biotechnology and Experimental Therapeutics** <noreply@ejmanager.com>  
 Date: Thu, 30 Sept 2021 at 09:45  
 Subject: Article Revision Letter for Authors - (JABET-2021-09-084)  
 To: <talhabmb@bgctub.ac.bd>

Dear Dr. Talha Bin Emran,

Your manuscript entitled "Morphology, Diversity and Phylogenetic Analysis of Spodoptera exigua (Lepidoptera: Noctuidae) in North Sulawesi by Employing Partial Mitochondrial Cytochrome Oxidase I Gene Sequences" (Ms.Nr. JABET-2021-09-084) was reviewed by editorial board members of the Journal of Advanced Biotechnology and Experimental Therapeutics. As initial decision, your manuscript was found interesting but some revisions have to be made before it can reach a publishable value.

Please answer all the comments below point-by-point in an accompanying response letter to your revised submission. And mark any corrections/editing with RED color in text the manuscript.

Within 21 days, you should send your revised manuscript via the online system of eJManager on my.ejmanager.com.

Best Regards  
 Journal of Advanced Biotechnology and Experimental Therapeutics  
 jabet.editor@gmail.com or jabet.editor@bsmiab.org  
 http://my.ejmanager.com/jabet  
 http://www.bsmiab.org/jabet  
 Phone:+821086737008

COMMENTS for Authors:

=&gt; Reviewer # 1

The Manuscript titled; Morphology, Diversity and Phylogenetic Analysis of Spodoptera exigua (Lepidoptera: Noctuidae) in North Sulawesi by Employing Partial Mitochondrial Cytochrome Oxidase I Gene Sequences by Satiman et al. attempted to study the phylogeny of Spodoptera exigua using mitochondrial CO1 gene sequences. I found this is an interesting study. Therefore, the Manuscript can be accepted after major revision.

1. Spodoptera exigua Hübner, 1808 (you need to include the year too)
2. CO1 not COI; fix it
3. How many Indonesian populations were studied in this study? And what are the CO1 gene sequence size of each population?
4. Line 70: 19.00 -20.00 what does it mean? Time?
5. Line 80: What kind of modification? Mention it.
6. Line 95: PCR premix or master mix
7. Line 97: Primer sequence should be in capital letter
8. Line 97: and not dan

- 9. Line 89: Please mention the modified protocol, slight modification is not adequate
- 10. Line 123: ML but in the tree (Fig 3), I can see it is NJ tree
- 11. How did you perform the model test?
- 12. Why K2P model test? How did you get it?
- 13. Table 5: Show the distances as percentage in the lower diagonal and nucleotide difference on the upper diagonal.
- 14. Perform ML analysis

=> Reviewer # 2

- If there is any statistical analysis, it should be mentioned at the end of the method section and in figures or tables using \* or #.
- Authors contribution is to be mentioned.
- All References to be properly cited and formatted....such errors: Feng H-Q, Wu K-M, Cheng D-F, Guo Y-Y.

\*\*\*\*\*

JOURNAL CONTACT EMAIL: [jabet.editor@gmail.com](mailto:jabet.editor@gmail.com)

IMPORTANT: USE JOURNAL CONTACT EMAIL for your messages. Do not answer to this email. It is not checked for messages

<http://www.ejmanager.com>

\*\*\*\*\*



Sender notified by  
Mailtrack